The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy

Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of hear...

Full description

Bibliographic Details
Main Authors:	Vamsi C. Gaddipati, Aarti A. Patel, Adam J. Cohen
Format:	Article
Language:	English
Published:	Hindawi Limited 2017-01-01
Series:	Case Reports in Cardiology
Online Access:	http://dx.doi.org/10.1155/2017/9561405

id	doaj-90a3951d38584e5eab5d9ad62faad30c
record_format	Article
spelling	doaj-90a3951d38584e5eab5d9ad62faad30c2020-11-24T20:47:57ZengHindawi LimitedCase Reports in Cardiology2090-64042090-64122017-01-01201710.1155/2017/95614059561405The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated CardiomyopathyVamsi C. Gaddipati0Aarti A. Patel1Adam J. Cohen2Department of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USADepartment of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USADepartment of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USAPeripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of heart failure. Pregnancy-associated cardiomyopathy (PACM) is a similar condition that refers to patients who develop such symptoms prior to the last month of pregnancy. We report the case of a nulliparous Caucasian female who develops early, severe PACM during her first pregnancy with postpartum persistence of New York Heart Association class II-III symptoms despite medical therapy. The use of the novel heart failure agent, sacubitril/valsartan (Entresto), is initiated with near-complete resolution of her symptoms.http://dx.doi.org/10.1155/2017/9561405
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Vamsi C. Gaddipati Aarti A. Patel Adam J. Cohen
spellingShingle	Vamsi C. Gaddipati Aarti A. Patel Adam J. Cohen The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy Case Reports in Cardiology
author_facet	Vamsi C. Gaddipati Aarti A. Patel Adam J. Cohen
author_sort	Vamsi C. Gaddipati
title	The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy
title_short	The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy
title_full	The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy
title_fullStr	The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy
title_full_unstemmed	The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy
title_sort	use of a novel heart failure agent in the treatment of pregnancy-associated cardiomyopathy
publisher	Hindawi Limited
series	Case Reports in Cardiology
issn	2090-6404 2090-6412
publishDate	2017-01-01
description	Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of heart failure. Pregnancy-associated cardiomyopathy (PACM) is a similar condition that refers to patients who develop such symptoms prior to the last month of pregnancy. We report the case of a nulliparous Caucasian female who develops early, severe PACM during her first pregnancy with postpartum persistence of New York Heart Association class II-III symptoms despite medical therapy. The use of the novel heart failure agent, sacubitril/valsartan (Entresto), is initiated with near-complete resolution of her symptoms.
url	http://dx.doi.org/10.1155/2017/9561405
work_keys_str_mv	AT vamsicgaddipati theuseofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT aartiapatel theuseofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT adamjcohen theuseofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT vamsicgaddipati useofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT aartiapatel useofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy AT adamjcohen useofanovelheartfailureagentinthetreatmentofpregnancyassociatedcardiomyopathy
_version_	1716809474429157376

The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy

Similar Items